Cargando…
Targeting canine bladder transitional cell carcinoma with a human bladder cancer-specific ligand
OBJECTIVE: To determine if a human bladder cancer-specific peptide named PLZ4 can target canine bladder cancer cells. EXPERIMENTAL DESIGN: The binding of PLZ4 to five established canine invasive transitional cell carcinoma (TCC) cell lines and to normal canine bladder urothelial cells was determined...
Autores principales: | , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3040722/ https://www.ncbi.nlm.nih.gov/pubmed/21272294 http://dx.doi.org/10.1186/1476-4598-10-9 |
_version_ | 1782198364136275968 |
---|---|
author | Lin, Tzu-yin Zhang, Hongyong Wang, Sisi Xie, Li Li, Bin Rodriguez, Carlos O de Vere White, Ralph Pan, Chong-xian |
author_facet | Lin, Tzu-yin Zhang, Hongyong Wang, Sisi Xie, Li Li, Bin Rodriguez, Carlos O de Vere White, Ralph Pan, Chong-xian |
author_sort | Lin, Tzu-yin |
collection | PubMed |
description | OBJECTIVE: To determine if a human bladder cancer-specific peptide named PLZ4 can target canine bladder cancer cells. EXPERIMENTAL DESIGN: The binding of PLZ4 to five established canine invasive transitional cell carcinoma (TCC) cell lines and to normal canine bladder urothelial cells was determined using the whole cell binding assay and an affinitofluorescence assay. The WST-8 assay was performed to determine whether PLZ4 affected cell viability. In vivo tumor-specific homing/targeting property and biodistribution of PLZ4 was performed in a mouse xenograft model via tail vein injection and was confirmed with ex vivo imaging. RESULTS: PLZ4 exhibited high affinity and specific dose-dependent binding to canine bladder TCC cell lines, but not to normal canine urothelial cells. No significant changes in cell viability or proliferation were observed upon incubation with PLZ4. The in vivo and ex vivo optical imaging study showed that, when linked with the near-infrared fluorescent dye Cy5.5, PLZ4 substantially accumulated at the canine bladder cancer foci in the mouse xenograft model as compared to the control. CONCLUSIONS AND CLINICAL RELEVANCE: PLZ4 can specifically bind to canine bladder cancer cells. This suggests that the preclinical studies of PLZ4 as a potential diagnostic and therapeutic agent can be performed in dogs with naturally occurring bladder cancer, and that PLZ4 can possibly be developed in the management of canine bladder cancer. |
format | Text |
id | pubmed-3040722 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-30407222011-02-18 Targeting canine bladder transitional cell carcinoma with a human bladder cancer-specific ligand Lin, Tzu-yin Zhang, Hongyong Wang, Sisi Xie, Li Li, Bin Rodriguez, Carlos O de Vere White, Ralph Pan, Chong-xian Mol Cancer Short Communication OBJECTIVE: To determine if a human bladder cancer-specific peptide named PLZ4 can target canine bladder cancer cells. EXPERIMENTAL DESIGN: The binding of PLZ4 to five established canine invasive transitional cell carcinoma (TCC) cell lines and to normal canine bladder urothelial cells was determined using the whole cell binding assay and an affinitofluorescence assay. The WST-8 assay was performed to determine whether PLZ4 affected cell viability. In vivo tumor-specific homing/targeting property and biodistribution of PLZ4 was performed in a mouse xenograft model via tail vein injection and was confirmed with ex vivo imaging. RESULTS: PLZ4 exhibited high affinity and specific dose-dependent binding to canine bladder TCC cell lines, but not to normal canine urothelial cells. No significant changes in cell viability or proliferation were observed upon incubation with PLZ4. The in vivo and ex vivo optical imaging study showed that, when linked with the near-infrared fluorescent dye Cy5.5, PLZ4 substantially accumulated at the canine bladder cancer foci in the mouse xenograft model as compared to the control. CONCLUSIONS AND CLINICAL RELEVANCE: PLZ4 can specifically bind to canine bladder cancer cells. This suggests that the preclinical studies of PLZ4 as a potential diagnostic and therapeutic agent can be performed in dogs with naturally occurring bladder cancer, and that PLZ4 can possibly be developed in the management of canine bladder cancer. BioMed Central 2011-01-27 /pmc/articles/PMC3040722/ /pubmed/21272294 http://dx.doi.org/10.1186/1476-4598-10-9 Text en Copyright ©2011 Lin et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Short Communication Lin, Tzu-yin Zhang, Hongyong Wang, Sisi Xie, Li Li, Bin Rodriguez, Carlos O de Vere White, Ralph Pan, Chong-xian Targeting canine bladder transitional cell carcinoma with a human bladder cancer-specific ligand |
title | Targeting canine bladder transitional cell carcinoma with a human bladder cancer-specific ligand |
title_full | Targeting canine bladder transitional cell carcinoma with a human bladder cancer-specific ligand |
title_fullStr | Targeting canine bladder transitional cell carcinoma with a human bladder cancer-specific ligand |
title_full_unstemmed | Targeting canine bladder transitional cell carcinoma with a human bladder cancer-specific ligand |
title_short | Targeting canine bladder transitional cell carcinoma with a human bladder cancer-specific ligand |
title_sort | targeting canine bladder transitional cell carcinoma with a human bladder cancer-specific ligand |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3040722/ https://www.ncbi.nlm.nih.gov/pubmed/21272294 http://dx.doi.org/10.1186/1476-4598-10-9 |
work_keys_str_mv | AT lintzuyin targetingcaninebladdertransitionalcellcarcinomawithahumanbladdercancerspecificligand AT zhanghongyong targetingcaninebladdertransitionalcellcarcinomawithahumanbladdercancerspecificligand AT wangsisi targetingcaninebladdertransitionalcellcarcinomawithahumanbladdercancerspecificligand AT xieli targetingcaninebladdertransitionalcellcarcinomawithahumanbladdercancerspecificligand AT libin targetingcaninebladdertransitionalcellcarcinomawithahumanbladdercancerspecificligand AT rodriguezcarloso targetingcaninebladdertransitionalcellcarcinomawithahumanbladdercancerspecificligand AT deverewhiteralph targetingcaninebladdertransitionalcellcarcinomawithahumanbladdercancerspecificligand AT panchongxian targetingcaninebladdertransitionalcellcarcinomawithahumanbladdercancerspecificligand |